肝细胞癌免疫治疗新兴生物标志物的现状和挑战 (综述)

Mo Cheng1, Xiufeng Zheng1, Jing Wei1

  • 1Department of Medical Oncology, Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.

概括

肝细胞癌 (HCC) 治疗正在通过免疫疗法推进. 像PD-1/PD-L1这样的生物标志物对于识别将从这些创新疗法中受益的患者至关重要.